TL-20-E2D448 SYGNOMICS Report
01/09/2022
SOC Drugs
# 1. Target: GSR
Drugs
Model Evidence
7 regulons containing the target(s), GSR are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
Glioblastoma Clinical Trials
Network Plots
Drugs in GBM Trials
# 1. Target: RRM2
Drugs
Model Evidence
12 regulons containing the target(s), RRM2 are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
Glioblastoma Clinical Trials
Network Plots
2. Target: TYMS
Drugs
Model Evidence
2 regulons containing the target(s), TYMS are overactive in this patient.
Hallmarks Enrichment
HALLMARK_E2F_TARGETS HALLMARK_G2M_CHECKPOINT HALLMARK_MYC_TARGETS_V1 HALLMARK_MITOTIC_SPINDLE HALLMARK_MTORC1_SIGNALING
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
Network Plots
3. Target: ALK
Drugs
Model Evidence
2 regulons containing the target(s), ALK are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
Network Plots
FDA Approved Drugs
# 1. Target: MAOB
Drugs
Model Evidence
3 regulons containing the target(s), MAOB are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
2. Target: TYMS
Drugs
Model Evidence
2 regulons containing the target(s), TYMS are overactive in this patient.
Hallmarks Enrichment
HALLMARK_E2F_TARGETS HALLMARK_G2M_CHECKPOINT HALLMARK_MYC_TARGETS_V1 HALLMARK_MITOTIC_SPINDLE HALLMARK_MTORC1_SIGNALING
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
Network Plots
3. Target: ALK
Drugs
Model Evidence
2 regulons containing the target(s), ALK are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
4. Target: SV2A
Drugs
Model Evidence
2 regulons containing the target(s), SV2A are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
5. Target: KEAP1
Drugs
Model Evidence
4 regulons containing the target(s), KEAP1 are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
Network Plots
6. Target: VKORC1
Drugs
Model Evidence
2 regulons containing the target(s), VKORC1 are overactive in this patient.
Hallmarks Enrichment
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
7. Target: GSR
Drugs
Model Evidence
7 regulons containing the target(s), GSR are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
8. Target: ABL1
Drugs
Model Evidence
5 regulons containing the target(s), ABL1 are overactive in this patient.
Hallmarks Enrichment
Literature Evidence
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
9. Target: LOXL2
Drugs
Model Evidence
1 regulons containing the target(s), LOXL2 are overactive in this patient.
Hallmarks Enrichment
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
10. Target: BSG
Drugs
Model Evidence
2 regulons containing the target(s), BSG are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
11. Target: NDUFA13
Drugs
Model Evidence
5 regulons containing the target(s), NDUFA13 are overactive in this patient.
Hallmarks Enrichment
HALLMARK_OXIDATIVE_PHOSPHORYLATION HALLMARK_DNA_REPAIR HALLMARK_MYC_TARGETS_V1
Literature Evidence
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
12. Target: TSG101
Drugs
Model Evidence
2 regulons containing the target(s), TSG101 are overactive in this patient.
Hallmarks Enrichment
HALLMARK_OXIDATIVE_PHOSPHORYLATION HALLMARK_DNA_REPAIR HALLMARK_MYC_TARGETS_V1
Literature Evidence
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
13. Target: NOTCH1
Drugs
Model Evidence
4 regulons containing the target(s), NOTCH1 are overactive in this patient.
Hallmarks Enrichment
HALLMARK_NOTCH_SIGNALING HALLMARK_WNT_BETA_CATENIN_SIGNALING
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
14. Target: ABAT
Drugs
Model Evidence
17 regulons containing the target(s), ABAT are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
15. Target: CHKA
Drugs
Model Evidence
3 regulons containing the target(s), CHKA are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
16. Target: NQO1
Drugs
Model Evidence
2 regulons containing the target(s), NQO1 are overactive in this patient.
Hallmarks Enrichment
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
17. Target: PLA2G2A
Drugs
Model Evidence
2 regulons containing the target(s), PLA2G2A are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
18. Target: ELN
Drugs
Model Evidence
1 regulons containing the target(s), ELN are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
19. Target: TRPV4
Drugs
Model Evidence
1 regulons containing the target(s), TRPV4 are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
20. Target: RRM2
Drugs
Model Evidence
12 regulons containing the target(s), RRM2 are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
21. Target: EEF2
Drugs
Model Evidence
10 regulons containing the target(s), EEF2 are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
22. Target: MAPK1,MAPK3
Drugs
Model Evidence
18 regulons containing the target(s), MAPK1,MAPK3 are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
Network Plots
23. Target: HSPA8
Drugs
Model Evidence
27 regulons containing the target(s), HSPA8 are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
24. Target: ATP1A1
Drugs
Model Evidence
66 regulons containing the target(s), ATP1A1 are overactive in this patient.
Hallmarks Enrichment
HALLMARK_TNFA_SIGNALING_VIA_NFKB HALLMARK_UV_RESPONSE_DN HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION HALLMARK_TGF_BETA_SIGNALING
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
25. Target: PLA2G2A,PLA2G5
Drugs
Model Evidence
7 regulons containing the target(s), PLA2G2A,PLA2G5 are overactive in this patient.
Hallmarks Enrichment
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION HALLMARK_TNFA_SIGNALING_VIA_NFKB
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
26. Target: SLC6A9
Drugs
Model Evidence
13 regulons containing the target(s), SLC6A9 are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
27. Target: APP
Drugs
Model Evidence
35 regulons containing the target(s), APP are overactive in this patient.
Hallmarks Enrichment
Literature Evidence
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
28. Target: SOD1
Drugs
Model Evidence
5 regulons containing the target(s), SOD1 are overactive in this patient.
Hallmarks Enrichment
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
29. Target: ACVR2B
Drugs
Model Evidence
5 regulons containing the target(s), ACVR2B are overactive in this patient.
Hallmarks Enrichment
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
30. Target: OXTR
Drugs
Model Evidence
9 regulons containing the target(s), OXTR are overactive in this patient.
Hallmarks Enrichment
None
Literature Evidence
No additional evidence was found
Glioblastoma Clinical Trials
No glioblastoma clinical trials were found for these drugs.
Network Plots
***Warning message: Missing column names filled in: ‘X15’ [15], ‘X16’ [16], ‘X17’ [17], ‘X18’ [18], ‘X19’ [19], ‘X20’ [20], ‘X21’ [21], ‘X22’ [22], ‘X23’ [23], ‘X24’ [24], ‘X25’ [25], ‘X26’ [26], ‘X27’ [27], ‘X28’ [28], ‘X29’ [29], ‘X30’ [30], ‘X31’ [31], ‘X32’ [32], ‘X33’ [33], ‘X34’ [34], ‘X35’ [35], ‘X36’ [36], ‘X37’ [37], ‘X38’ [38], ‘X39’ [39], ‘X40’ [40], ‘X41’ [41], ‘X42’ [42], ‘X43’ [43], ‘X44’ [44], ‘X45’ [45], ‘X46’ [46], ‘X47’ [47], ‘X48’ [48], ‘X49’ [49], ‘X50’ [50], ‘X51’ [51], ‘X52’ [52], ‘X53’ [53], ‘X54’ [54], ‘X55’ [55], ‘X56’ [56], ‘X57’ [57], ‘X58’ [58], ‘X59’ [59], ‘X60’ [60], ‘X61’ [61], ‘X62’ [62], ‘X63’ [63], ‘X64’ [64], ‘X65’ [65], ‘X66’ [66], ‘X67’ [67], ‘X68’ [68], ‘X69’ [69], ‘X70’ [70], ‘X71’ [71], ‘X72’ [72], ‘X73’ [73], ‘X74’ [74], ‘X75’ [75], ‘X76’ [76], ‘X77’ [77], ‘X78’ [78], ‘X79’ [79], ‘X80’ [80], ‘X81’ [81], ‘X82’ [82], ‘X83’ [83], ‘X84’ [84], ‘X85’ [85], ‘X86’ [86], ‘X87’ [87], ‘X88’ [88], ‘X89’ [89], ‘X90’ [90], ‘X91’ [91], ‘X92’ [92], ‘X93’ [93], ‘X94’ [94], ‘X95’ [9 [… truncated]